Pierluigi Porcu, MD

Pierluigi Porcu, MD

Contact Dr. Porcu

834 Chestnut Street
Suite 320
Philadelphia, PA 19107

(215) 955-8874
(215) 955-9641 fax

Most Recent Peer-reviewed Publications

  1. Duvelisib, a novel oral dual inhibitor of PI3K-d,g, is clinically active in advanced hematologic malignancies
  2. Activity of the PI3K-δ,g inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
  3. Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma
  4. Editorial: Murine models of leukemia and lymphoma
  5. A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas
  6. Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome
  7. Expanding and expounding the genomic map of CTCL
  8. A positive randomised trial in cutaneous T-cell lymphoma
  9. Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas
  10. Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL)
  11. NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines
  12. Overview of the use of murine models in leukemia and lymphoma research
  13. Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?
  14. MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sèzary syndrome patients
  15. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: A multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium
  16. Sézary Syndrome: Clinical and Biological Aspects
  17. Cutaneous mantle cell lymphoma: a clinicopathologic review of 10 cases
  18. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases
  19. Mechanism, consequences, and therapeutic targeting of abnormal IL15 signaling in cutaneous T-cell lymphoma
  20. NCCN Guidelines® insights: Non-Hodgkin's lymphomas, version 3.2016 featured updates to the NCCN guidelines